Adam Sherwat, the director of the Office of Infectious Diseases within the FDA’s Center for Drug Evaluation and Research, is departing from the agency.
This leadership transition may affect the FDA's capacity to manage infectious disease evaluations and regulatory processes.
The implications of this change could extend to ongoing and future drug assessments, particularly in the context of public health responses.